Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
“Using PD-1 and PD-L1 inhibitors reactivates NK cell anti-tumor responses [116].”
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Roles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Self-citationThe Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 602
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
“antitumor immunity and that PD-1 NK cells present at the tumor site display an exhausted phenotype.(109) In humans, in addition to PD-1, other inhibitory checkpoints are expressed not only by T lymphocytes but also by NK cells.”
Patsoukis, N., Wang, Q., Strauss, L., & Boussiotis, V. A. (2020) · Science Advances · doi:10.1126/sciadv.abd2712 · Cited by 535
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
“For example, MDSCs express immune-checkpoint molecules, such as PD-L1, that can inhibit the antitumour functions of T cells and NK cells 81,82 .”
Turning cold tumors hot: from molecular mechanisms to clinical applications
Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
“Both CTLA4 and PD-1 are expressed by activated NK cells [205, 206] and NK anti-cancer activity can be enhanced by disrupting these signaling pathways [207, 208].”
BackgroundMeric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1963 · Cited by 418
NK Cell-Based Immune Checkpoint Inhibition
Khan, M., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 356
“Therefore, the combinations of immune checkpoint inhibitors, such as CTLA-4 and PD-1 inhibitors, that are being tried for synergistic response targeting T cells could also be tried in the context of NK cells (368), as anti-PD-1 and anti-PD-L1 inhibitors have also been shown to enhance NK cell-mediated cytotoxicity (34…”
BackgroundPathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis
Cao, C., Yu, M., & Chai, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2015-1 · Cited by 354
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Ni, J., Wang, X., Stojanovic, A., Zhang, Q., Wincher, M., Bühler, L., Arnold, A., Correia, M. P., Winkler, M., Koch, P.-S., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.001 · Cited by 324
Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y., Raabe, M., Thel, H., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 294
“Similarly, NK cells have become recognized as a potential effector cell for anti-PD-1/PD-L1 therapies 44,45 .”
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
“PD-1 is expressed not only in T cells in peripheral tissues but also in B cells, activated monocytes, DCs and NK cells.(187,188) TAMs express high levels of PD-1 compared to splenic macrophages or circulating monocytes, and PD-1 expression increases with tumor volume after engraftment.”
BackgroundChen, S., Zhu, H., & Jounaidi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02005-w · Cited by 234
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., & Yu, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1085-3 · Cited by 286
NK cells and ILCs in tumor immunotherapy
Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., et al. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100870 · Cited by 270
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Nakamura, T., Sato, T., Endo, R., Sasaki, S., Takahashi, N., Sato, Y., Hyodo, M., Hayakawa, Y., & Harashima, H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002852 · Cited by 257
NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists
Nicolai, C. J., Wolf, N., Chang, I.-C., Kirn, G., Marcus, A., Ndubaku, C. O., McWhirter, S. M., & Raulet, D. H. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz2738 · Cited by 268
Self-citationMacroscale biomaterials strategies for local immunomodulation
Dellacherie, M. O., Seo, B. R., & Mooney, D. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0106-3 · Cited by 255
Targeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
Allogeneic natural killer cell therapy
Berrien-Elliott, M. M., Jacobs, M. T., & Fehniger, T. A. (2023) · Blood · doi:10.1182/blood.2022016200 · Cited by 224
Camouflage strategies for therapeutic exosomes evasion from phagocytosis
Parada, N., Romero-Trujillo, A., Georges, N., & Alcayaga-Miranda, F. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.01.001 · Cited by 230
“First discovered in T cell, PD-1 is expressed by a variety of hematopoietic cells like B, NK, dendritic cells and macrophages [24,88,90], and is considered an immune checkpointmolecule that plays an important role in downregulating the immune system proinflammatory activity [90].”
BackgroundDevelopment of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities
Claridge, B., Lozano, J., Poh, Q. H., & Greening, D. W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.734720 · Cited by 227
Daher, M., & Rezvani, K. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0556 · Cited by 219
“Other inhibitory molecules under investigation in NK cells include the classic T-cell checkpoints PD-1 and CTLA4 (67, 68).”
BackgroundKillers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 217
“Notably, even in this case, NK cells were essential for the full therapeutic effect of PD-L1 blockade (143).”
BackgroundSelf-citationJudge, S. J., Murphy, W. J., & Canter, R. J. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00049 · Cited by 197
Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy
Huang, J., Xiao, Z., An, Y., Han, S., Wu, W., Wang, Y., Guo, Y., & Shuai, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120636 · Cited by 209
Nersesian, S., Schwartz, S. L., Grantham, S. R., MacLean, L. K., Lee, S. N., Pugh-Toole, M., & Boudreau, J. E. (2021) · Translational Oncology · doi:10.1016/j.tranon.2020.100930 · Cited by 197
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 191
Natural Killer Cells: From Innate to Adaptive Features
Mujal, A. M., Delconte, R. B., & Sun, J. C. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-074948 · Cited by 189
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel, J.-C., Crozat, K., Dalod, M., & Mattiuz, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00009 · Cited by 194
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
Merino, A., Zhang, B., Dougherty, P., Luo, X., Wang, J., Blazar, B. R., Miller, J. S., & Cichocki, F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125916 · Cited by 184
“PD-1 expression was observed on the majority of tumor-infiltrating NK cells, but PD-1+ cells were not dysfunctional as determined ex vivo by functional responsiveness to engagement of activating receptors (56).”
BackgroundImmune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Cao, Y., Wang, X., Jin, T., Tian, Y., Dai, C., Widarma, C., Song, R., & Xu, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00348-8 · Cited by 180
Chemo-Immunotherapy: A New Trend in Cancer Treatment
Sordo-Bahamonde, C., Lorenzo-Herrero, S., Gonzalez-Rodriguez, A. P., Martínez-Pérez, A., Rodrigo, J. P., García-Pedrero, J. M., & Gonzalez, S. (2023) · Cancers · doi:10.3390/cancers15112912 · Cited by 176
“Interestingly, the response to PD-1 blockade may be enhanced by the increased number and activation of NK cells, thereby improving the clinical effectiveness, particularly in MHC class I-defective tumors [46–49].”
BackgroundPD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 187
“These findings strongly suggest a possible role for NK cells in immunotherapeutic strategies targeting the PD-1/PD-L1 axis particularly against HLA-I deficient tumor cells, but, interestinlgy, NK responses were still important for controlling cancer development also in cancer models in which CD8 T cells played a subst…”
BackgroundA Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy
Pomeroy, E. J., Hunzeker, J. T., Kluesner, M. G., Lahr, W. S., Smeester, B. A., Crosby, M. R., Lonetree, C.-L., Yamamoto, K., Bendzick, L., Miller, J. S., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.009 · Cited by 195
WNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 179
Forks in the road for CAR T and CAR NK cell cancer therapies
Dagher, O. K., & Posey, A. D. (2023) · Nature Immunology · doi:10.1038/s41590-023-01659-y · Cited by 172
“53,93).”
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment
Zhang, H., Li, S., Wang, D., Liu, S. M., Xiao, T., Gu, W., Yang, H., Wang, H. Z., Yang, M., & Chen, P. (2024) · Biomarker Research · doi:10.1186/s40364-024-00646-1 · Cited by 214
“…that the PD-1/PD-L1 axis regulates NK cell phenotype in mouse models of melanoma, lymphoma, and colon cancer; moreover, they revealed that the inhibition of this pathway could significantly restore the anti-tumor function of NK cells, promoting the survival of hormone-treated mice [260].”
BackgroundAging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing
Li, C. M.-C., Shapiro, H., Tsiobikas, C., Selfors, L. M., Chen, H., Rosenbluth, J., Moore, K., Gupta, K. P., Gray, G. K., Oren, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108566 · Cited by 184
“Furthermore, expression of two immunosuppressive ligands targeting T cells and NK cells also increased—Cd274 (also known as Pd-l1) (Hsu et al., 2018; Lu et al., 2019; Yamazaki et al., 2002) and Lilrb4 (also known as Ilt3) (Cella et al., 1997; Deng et al., 2018; Suciu-Foca and Cortesini, 2007)…”
Chen, H., Chong, W., Wu, Q., Yao, Y., Mao, M., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01113 · Cited by 180
“Tumor-infiltrating immune cells results manifested LRP1B mutated samples were infiltrated in CD8 T cells, NK cells and activated CD4 memory T cells, which supported the previous observations that such leucocytes and pathways present predominately in the tumor microenvironment of immune responder and promote the immune…”
ResultZhang, D., Zheng, Y., Lin, Z., Liu, X., Li, J., Yang, H., & Tan, W. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202002145 · Cited by 181
Targeting macrophages in hematological malignancies: recent advances and future directions
Li, W., Wang, F., Guo, R., Bian, Z., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01328-x · Cited by 167
“Previous investigations have shown that PD-1 expression inhibits a wide variety of immune cells in the TME, consisting of T cells [128], B cells [129], NK cells [130], and DCs [131].”
BackgroundNatural Killer cells at the frontline in the fight against cancer
Coënon, L., Geindreau, M., Ghiringhelli, F., Villalba, M., & Bruchard, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06976-0 · Cited by 187
“The most known inhibitory axis is PD-1 and its two ligands, PD-L1 and PD-L2, which are overexpressed in some cancers, inhibiting NK cells anti-tumor activity [158, 159].”
BackgroundHigh-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Luchtel, R. A., Bhagat, T., Pradhan, K., Jacobs, W. R., Levine, M., Verma, A., & Shenoy, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908158117 · Cited by 167
“Apart from CD8+ T cells, granzyme B has been shown to be produced by NK cells (28, 29) and to a small extent by CD8− T cells (29).”
Aaes, T. L., & Vandenabeele, P. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00658-y · Cited by 169
Quatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 158
“The first mechanistic evidence for PD-1 as an important checkpoint for NK cell activation was found in MHC-deficient tumours: PD-1 expression was detected at a very early timepoint (48 h) after tumour inoculation on a subset of intratumoural NK cells [62].”
BackgroundResultInfluentialLi, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.004 · Cited by 158
CAR-NK Cells: From Natural Basis to Design for Kill
Khawar, M. B., & Sun, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707542 · Cited by 173
Zhao, L., Shi, W., Hu, F., Song, X., Cheng, Z., & Zhou, J. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112882 · Cited by 168
Carlsten, M., & Järås, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02357 · Cited by 176
“proposed that NK cells express PD1 and that blockade of the PD1/PDL1 interaction also activates NK cells that are indispensable for the therapeutic effect of these therapies (205).”
BackgroundRadiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8
Walle, T., Kraske, J. A., Liao, B., Lenoir, B., Timke, C., Halbach, E. V. B. U., Tran, F., Griebel, P., Albrecht, D., Ahmed, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abh4050 · Cited by 168
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies
Market, M., Angka, L., Martel, A. B., Bastin, D. J., Olanubi, O., Tennakoon, G., Boucher, D. M., Ng, J., Ardolino, M., & Auer, R. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01512 · Cited by 165
Self-citationNK Cell Dysfunction and Checkpoint Immunotherapy
Bi, J., & Tian, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01999 · Cited by 169
“PD-1 NK cells, unlike TIGIT, or CD96 NK cells, displayed stronger effector potentials than PD-1 NK cells, as shown by higher levels of IFN-γ and granzyme B upon IL-2 stimulation in vitro (116).”
BackgroundLeveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 165
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Blazar, B. R., Hill, G. R., & Murphy, W. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0356-4 · Cited by 158
NK cell exhaustion in the tumor microenvironment
Hao, J., Yang, H., Xiong, H., & Luo, K. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303605 · Cited by 160
“Blocking the PD-1/PD-L1 inhibitory axis has become a popular therapeutic strategy (137).”
BackgroundCancer cells educate natural killer cells to a metastasis-promoting cell state
Chan, I. S., Knútsdóttir, H., Ramakrishnan, G., Padmanaban, V., Warrier, M., Ramírez, J. C., Dunworth, M., Zhang, H., Jaffee, E. M., Bader, J. S., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202001134 · Cited by 156
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Tan, S., Xu, Y., Wang, Z., Wang, T., Du, X., Song, X., Guo, X., Peng, J., Zhang, J., Liang, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2332 · Cited by 147
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Judge, S. J., Dunai, C., Aguilar, E. G., Vick, S. C., Sturgill, I. R., Khuat, L. T., Stoffel, K. M., Dyke, J. V., Longo, D. L., Darrow, M. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133353 · Cited by 151
“This search for PD-1 expression and associated therapeutic targeting has also been applied to NK cells (11), leading to speculation that PD-1 inhibition is a viable mechanism for augmenting the therapeutic potential of NK cells, particularly for tumors refractory to T cell–based approaches due to low MHCI expression (…”
BackgroundMethodInfluentialTargeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 154
“PD1 is expressed mainly by T cells but activated NK cells also express PD1 receptor (Barry et al., 2018; Hsu et al., 2018; Mariotti et al., 2019; Quatrini et al., 2020).”
BackgroundPembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
Lin, M., Luo, H., Liang, S., Chen, J., Liu, A., Niu, L., & Jiang, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132712 · Cited by 149
“This is consistent with the results of previous studies showing that PD-L1 blockade enhances the antitumor efficacy of NK cells (38, 39).”
BackgroundResultClonal expansion of innate and adaptive lymphocytes
Adams, N. M., Grassmann, S. A., & Sun, J. C.-Y. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0307-4 · Cited by 155
Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 152
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Ben‐Shmuel, A., Biber, G., & Barda‐Saad, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00275 · Cited by 146
“Indeed, PD-1/PD-L1 blockade in mice bearing PD-L1 MHC-I tumors demonstrated the importance of NK cells for the efficacy of these treatments (120).”
BackgroundHan, X., Cheng, K., Xu, Y., Wang, Y., Min, H., Zhang, Y., Zhao, X., Zhao, R., Anderson, G. J., Ren, L., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12232 · Cited by 140
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
Munari, E., Mariotti, F. R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105123 · Cited by 151
“showed that in lymphoma mouse models, PD-1 is expressed on a discrete fraction of NK cells represented by the most activated and functionally responsive intratumoral NK population [41].”
BackgroundSenescent cells: Living or dying is a matter of NK cells
Antonangeli, F., Zingoni, A., Soriani, A., & Santoni, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0718-299r · Cited by 129
Rethinking immune checkpoint blockade: ‘Beyond the T cell’
Liu, X., Hogg, G. D., & DeNardo, D. G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001460 · Cited by 130
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
Sun, H., & Sun, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02354 · Cited by 123
“demonstrated in multiple tumor models that PD-1 is upregulated on the most activated and functionally responsive intratumoral NK cells, suggesting that the efficacy of PD-1 blockade depends in part on inducing an NK cell-based antitumor response (126).”
BackgroundImmune checkpoint inhibitor combinations: Current efforts and important aspects for success
Kon, E., & Benhar, I. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.004 · Cited by 129
“This suggests that immune cell types other than T cells may also play a role in PD-1 blockade (Hsu et al., 2018).”
BackgroundUeda, T., Kumagai, A., Iriguchi, S., Yasui, Y., Miyasaka, T., Nakagoshi, K., Nakane, K., Saito, K., Takahashi, M., Sasaki, A., et al. (2020) · Cancer Science · doi:10.1111/cas.14374 · Cited by 118
Natural Killer Cells: Tumor Surveillance and Signaling
Guzman, L. G. M., Keating, N., & Nicholson, S. E. (2020) · Cancers · doi:10.3390/cancers12040952 · Cited by 130
Zugazagoitia, J., Gupta, S., Liu, Y., Fuhrman, K., Gettinger, S., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0175 · Cited by 112
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Hsieh, Y.-C., Kirschner, K., & Copland, M. (2021) · Leukemia · doi:10.1038/s41375-021-01238-w · Cited by 123
“PD1/PDL1 blockade may therefore mediate some of its therapeutic effects through eliciting a strong NK response as demonstrated in murine cancer models [62].”
BackgroundIFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella
Lin, Q., Li, R., Jia, X., Li, R., Yu, B., Hu, J., Luo, X., Badea, S. R., Chen, X., Fu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22755-3 · Cited by 126
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer
Hasim, M. S., Marotel, M., Hodgins, J. J., Vulpis, E., Makinson, O. J., Asif, S., Shih, H., Scheer, A. K., MacMillan, O., Alonso, F., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj3286 · Cited by 14
“Consistent with what has been previously reported ( 38 , 45 ), murine NK cells acutely stimulated ex vivo with a panel of inflammatory mediators failed to up-regulate PD-1 at the protein level (fig.”
InfluentialSelf-citationArmand, P. A., Lesokhin, A. M., Borrello, I., Timmerman, J. M., Gutierrez, M. E., Zhu, L., McKiver, M. P., & Ansell, S. M. (2020) · Leukemia · doi:10.1038/s41375-020-0939-1 · Cited by 120
Yang, Y., Li, L., Jiang, Z., Wang, B., & Pan, Z. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02641-5 · Cited by 124
Engineering the next generation of CAR-NK immunotherapies
Biederstädt, A., & Rezvani, K. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03209-4 · Cited by 118
“Other groups are striving to translate the lessons learned in the context of T-cell immunobiology and are investigating the effects of PD-1/PD-L1 and CTLA-4 blockade on NK cells [62, 63].”
BackgroundNK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential
Portale, F., & Mitri, D. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119521 · Cited by 123
“NK cells embody a new opportunity that overcomes such limitations and is thus endowed with a promising therapeutic potential.”
InfluentialNK Cell-Based Immunotherapy in Cancer Metastasis
Lorenzo‐Herrero, S., López‐Soto, A., Sordo‐Bahamonde, C., González, A. P., Vitale, M., & Gonzalez, S. R. (2018) · Cancers · doi:10.3390/cancers11010029 · Cited by 119
“In fact, the PD1/PDL1 blockade in several mouse models elicited a strong NK cell-mediated response that was indispensable for the full therapeutic effect of immunotherapy [162].”
BackgroundZheng, G., Guo, Z., Li, W., Xi, W., Zuo, B., Zhang, R., Wen, W., Yang, A., & Jia, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00629-w · Cited by 120
“A recent study showed that the documented immune checkpoint PD-L1/ PD-1 is critically involved in trastuzumab resistance in breast cancer.(34,35) Consistent with previous reports, we observed that IFN-γ significantly increased the level of PD-L1 in breast cancer cells (Fig.”
ResultTargeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Zhang, C., & Liu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01295 · Cited by 113
“Although it is assumed that these checkpoint blockade therapies primarily rescue T cell’s antitumor efficacy, increasing evidence suggests that NK cells potentially respond to PD-1/PD-L1 blockade, particularly for MHC I-deficient tumors, as evidenced by attenuated antitumor efficacy after depletion of NK cells (70).”
BackgroundNovel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 114
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.